A Study for Older Adults With Acute Lymphoblastic Leukaemia (UKALL60+)

August 15, 2023 updated by: University College, London

A Phase 2 Study for Older Adults With Acute Lymphoblastic Leukaemia

The NCRI Adult ALL sub-group propose to collaborate with the Dutch/Belgian group HOVON to carry out a prospective, non randomised multi-arm study (including a choice of regimen intensity) to investigate the safety, tolerability and feasibility of a standardised therapy protocol for patients ≥ 60 years old with de novo ALL. The overall aim is define a basic standard of care upon which trials of novel therapies will be based in future. The design of the study will enable collection of a comprehensive dataset regarding the clinical outcome, Complete Response Rate (CR) and Minimal Residual Disease (MRD) response rates in a previously completely uncharacterised population, thus providing the essential platform for designing future randomised advanced phase studies in which new therapeutic approaches and novel therapies can be prospectively investigated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study will

  1. establish baseline expectations for Event Free Survival (EFS), Overall Survival (OS), MRD responses and quality of life measures for older patients of all ages and pre-morbid states;
  2. disclose how best to use knowledge of pre-morbid characteristics to apply the appropriate intensity of therapy in order to balance the best disease related outcomes against quality of life;
  3. establish national standards of care for this patient group;
  4. provide the essential platform for careful design of future randomised advanced phase studies of new therapeutic approaches and agents.

Study Type

Interventional

Enrollment (Actual)

126

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Rotterdam, Netherlands
        • Erasmus MC
  • United Kingdom
      • Airdrie, United Kingdom
        • NHS Lanarkshire - Monklands
      • Blackpool, United Kingdom
        • Blackpool Victoria Hopsital
      • Bournemouth, United Kingdom
        • Royal Bournemouth Hospital
      • Bradford, United Kingdom
        • Bradford Royal Infirmary
      • Bristol, United Kingdom
        • Bristol Haematology and Oncology Centre
      • Cardiff, United Kingdom
        • University Hospital of Wales
      • Cottingham, United Kingdom
        • Castle Hill Hospital
      • Dudley, United Kingdom
        • Russells Hall Hospital
      • Dundee, United Kingdom
        • Ninewells Hospital
      • Edinburgh, United Kingdom
        • NHS Lothian - Western General Hospital
      • Glasgow, United Kingdom
        • Beatson West of Scotland Cancer Centre
      • Glasgow, United Kingdom
        • New Victoria Hospital and Southern General Hospital
      • Harrow, United Kingdom
        • Northwick Park Hospital
      • Leeds, United Kingdom
        • St James' Hospital, Leeds
      • Leicester, United Kingdom
        • Leicester Royal Infirmary
      • Liverpool, United Kingdom
        • Royal Liverpool University Hospital
      • London, United Kingdom
        • St George's Hospital
      • London, United Kingdom
        • King's College Hospital NHS Foundation Trust
      • London, United Kingdom
        • St Bartholomew's Hospital
      • Manchester, United Kingdom
        • The Christie Hospital
      • Middlesbrough, United Kingdom
        • James Cook University Hospital
      • Oxford, United Kingdom
        • Churchill Hospital, Oxford
      • Plymouth, United Kingdom
        • Derriford Hospital
      • Poole, United Kingdom
        • Poole General Hospital
      • Prescot, United Kingdom
        • St Helen's & Knowlsey Teaching Hospitals
      • Salisbury, United Kingdom
        • Salisbury District Hospital
      • Sheffield, United Kingdom
        • Royal Hallamshire Hospital
      • Sutton, United Kingdom
        • Royal MarsdenHospital
      • Swindon, United Kingdom
        • Great Western Hospital
      • Taunton, United Kingdom
        • Musgrove Park
      • Torquay, United Kingdom
        • Torbay Hospital
      • West Bromwich, United Kingdom
        • Sandwell General Hospital
      • Wirral, United Kingdom
        • Arrowe Park Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

51 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 60 with Acute Lymphoblastic Leukaemia (ALL) OR ≥ 55 with Acute Lymphoblastic Leukaemia (ALL) unsuitable for the UKALL14 or HOVON 100 trial
  • Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days may be given before trial registration))
  • Willing and able to give consent

Exclusion Criteria:

  • Known HIV infection
  • Blast transformation of CML
  • Mature B-cell leukaemia i.e. Burkitts disease t(8,14)(q24 ;q32) and variant c-myc translocations e.g. t(2;8)(p12 ;q24), t(8;22)(q24;q11)
  • Women who are pregnant or lactating

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Philadelphia Positive Patients
All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
Drug: Chemotherapy
Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Experimental: Philadelphia -ve Patients- Intensive
Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
Drug: Chemotherapy
Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Experimental: Philadelphia -ve Patients- Intensive +
Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
Drug: Chemotherapy
Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Experimental: Philadelphia -ve Patients- Non Intensive
Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
Drug: Chemotherapy
Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
No Intervention: Registration only
Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complete remission rate after 2 phases of induction
Time Frame: Approximately 2 months after start of treatment
All patients will be assessed for their remission status at the end of Phase 2 induction. The CR rate at this timepoint will then be calculated.
Approximately 2 months after start of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complete remission rate after 1 phase of induction
Time Frame: Approximately 1 month after start of treatment
All patients will be assessed for their remission status at the end of Phase 1 induction. The CR rate at this timepoint will then be calculated.
Approximately 1 month after start of treatment
Overall Survival at 1 year
Time Frame: 1 year after registration
Overall survival for all patients will be measured 1 year after registration
1 year after registration
Prognostic significance of molecularly determined minimal residual disease (MRD) at various time-points during therapy with respect to relapse occurrence.
Time Frame: At diagnosis, 4 weeks, 8 weeks, 12 weeks after starting treatment
MRD levels will be measured at distinct timepoints during the trial.
At diagnosis, 4 weeks, 8 weeks, 12 weeks after starting treatment
Tolerability of treatment as determined by occurrence of key adverse effects
Time Frame: Approximately 4 weeks, 8 weeks, 12 weeks, 24 weeks after starting treatment
Patients in arms A-D will be assessed for adverse events at distinct timepoints during the trial
Approximately 4 weeks, 8 weeks, 12 weeks, 24 weeks after starting treatment
Duration of in-patient hospitalisation
Time Frame: Approximately 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28 after starting treatment and every 3 months during maintenance
All patients will be assessed for the number of days they have spent as in-patients at distinct timepoints during the trial.
Approximately 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28 after starting treatment and every 3 months during maintenance
Relationship between performance status/co-morbidity and treatment option chosen
Time Frame: At registration
At registration
Quality of life aspects assessed at diagnosis/baseline at various time points
Time Frame: Registration, Approximately 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28 after starting treatment, before starting maintenance and at the end of maintenance
Registration, Approximately 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28 after starting treatment, before starting maintenance and at the end of maintenance

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University College, London

Collaborators

Cancer Research UK
Stichting Hemato-Oncologie voor Volwassenen Nederland

Investigators

  • Principal Investigator: Prof Adele Fielding, University College London Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2012

Primary Completion (Actual)

December 21, 2018

Study Completion (Actual)

February 1, 2023

Study Registration Dates

First Submitted

June 7, 2012

First Submitted That Met QC Criteria

June 8, 2012

First Posted (Estimated)

June 11, 2012

Study Record Updates

Last Update Posted (Actual)

August 16, 2023

Last Update Submitted That Met QC Criteria

August 15, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UCL/11/0532

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Lymphoblastic Leukaemia

Clinical Trials on Chemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe